Abstract
In the past twenty years, more than thirty peptides have been discovered to be present in the mammalian central nervous system (CNS). As the neuroanatomical distribution, neurochemical, electrophysiological and pharmacobehavioral effects of this novel group of neuroregulators have been described, it is evident that certain of these peptide-containing neural circuits may be pathologically altered in neuropsychiatric disorders. Although much attention has been focused on the opioid peptides, substantial data strongly support the hypothesis that non-opioid peptides such as somatostatin, neurotensin and substance P are altered in a diverse number of neuropsychiatric disorders including Alzheimer's disease, Huntington's chorea, Parkinson's disease, major depression and schizophrenia.
| Original language | English |
|---|---|
| Pages (from-to) | 333-341 |
| Number of pages | 9 |
| Journal | Progress in Clinical and Biological Research |
| Volume | 192 |
| State | Published - Dec 1 1985 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Involvement of non-opioid peptides in the pathogenesis of neurological and psychiatric disorders : evidence from CSF and post-mortem studies. / Nemeroff, Charles; Bissette, G.
In: Progress in Clinical and Biological Research, Vol. 192, 01.12.1985, p. 333-341.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Involvement of non-opioid peptides in the pathogenesis of neurological and psychiatric disorders
T2 - evidence from CSF and post-mortem studies.
AU - Nemeroff, Charles
AU - Bissette, G.
PY - 1985/12/1
Y1 - 1985/12/1
N2 - In the past twenty years, more than thirty peptides have been discovered to be present in the mammalian central nervous system (CNS). As the neuroanatomical distribution, neurochemical, electrophysiological and pharmacobehavioral effects of this novel group of neuroregulators have been described, it is evident that certain of these peptide-containing neural circuits may be pathologically altered in neuropsychiatric disorders. Although much attention has been focused on the opioid peptides, substantial data strongly support the hypothesis that non-opioid peptides such as somatostatin, neurotensin and substance P are altered in a diverse number of neuropsychiatric disorders including Alzheimer's disease, Huntington's chorea, Parkinson's disease, major depression and schizophrenia.
AB - In the past twenty years, more than thirty peptides have been discovered to be present in the mammalian central nervous system (CNS). As the neuroanatomical distribution, neurochemical, electrophysiological and pharmacobehavioral effects of this novel group of neuroregulators have been described, it is evident that certain of these peptide-containing neural circuits may be pathologically altered in neuropsychiatric disorders. Although much attention has been focused on the opioid peptides, substantial data strongly support the hypothesis that non-opioid peptides such as somatostatin, neurotensin and substance P are altered in a diverse number of neuropsychiatric disorders including Alzheimer's disease, Huntington's chorea, Parkinson's disease, major depression and schizophrenia.
UR - http://www.scopus.com/inward/record.url?scp=0022333186&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022333186&partnerID=8YFLogxK
M3 - Article
C2 - 2934745
AN - SCOPUS:0022333186
VL - 192
SP - 333
EP - 341
JO - Progress in Clinical and Biological Research
JF - Progress in Clinical and Biological Research
SN - 0361-7742
ER -